Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis

@inproceedings{Jurez2017HalofuginoneIT,
  title={Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis},
  author={Patricia Ju{\'a}rez and Pierrick G. J. Fournier and Khalid S. Mohammad and Ryan C. McKenna and Holly W. Davis and Xiang Hong Peng and Maria Niewolna and Alain Mauviel and John M. Chirgwin and Theresa A. Guise},
  booktitle={Oncotarget},
  year={2017}
}
More efficient therapies that target multiple molecular mechanisms are needed for the treatment of incurable bone metastases. Halofuginone is a plant alkaloid-derivative with antiangiogenic and antiproliferative effects. Here we demonstrate that halofuginone is an effective therapy for the treatment of bone metastases, through multiple actions that include inhibition of TGFβ and BMP-signaling. Halofuginone blocked TGF-β-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-β-induced… CONTINUE READING